Moderna (MRNA)
(Delayed Data from NSDQ)
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Zacks News
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 64.29% and 2.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports third-quarter earnings.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $79.76, moving +1.42% from the previous trading session.
Moderna (MRNA) Stock Moves -0.37%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $86.01, marking a -0.37% move from the previous day.
Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View
by Zacks Equity Research
Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.
Markets Pop on Bargain Hunting, Stronger Economy
by Mark Vickery
The small-cap Russell 2000, still under water over the past month, led the way higher today.
J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off
by Zacks Equity Research
J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Moderna (MRNA) stood at $102.76, denoting a -1.6% change from the preceding trading day.
Novavax (NVAX) Focuses on Diversifying Vaccines Portfolio
by Zacks Equity Research
Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indications.
Alexandria (ARE) Receives Rating Affirmation From Moody's
by Zacks Equity Research
Underpinning Alexandria's (ARE) solid operating and financial performance, Moody's Investors Service reaffirms the company's credit ratings of Baa1 and maintains its outlook rating at stable.
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
by Zacks Equity Research
Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
by Zacks Equity Research
Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.
Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study
by Zacks Equity Research
Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $104.26, marking a +1.14% move from the previous day.
Novavax (NVAX) Up 8% on FDA Nod for Updated COVID Booster Jab
by Zacks Equity Research
Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.
Alexandria (ARE) Expedites Delivery of Moderna's New HQ
by Zacks Equity Research
Alexandria (ARE) to hand over the new global headquarters and core R&D operations center to Moderna in November 2023. ARE will benefit from the project's incremental annual net operating income.
The Zacks Analyst Blog Highlights Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours
by Zacks Equity Research
Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours are included in this Analyst Blog.
Top Stock Reports for Intel, Anheuser-Busch & HCA Healthcare
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Intel Corporation (INTC), Anheuser-Busch InBev SA/NV (BUD) and HCA Healthcare, Inc. (HCA).
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
by Shaun Pruitt
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $100.27, marking a +0.83% move from the previous day.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $99.99, moving -0.24% from the previous trading session.